FIGURE 2 from Multi-omics Analysis of a Fecal Microbiota Transplantation Trial Identifies Novel Aspects of Acute GVHD Pathogenesis

Microbiota clusters and aGVHD risk. A, Principal coordinates analysis of early post-FMT/placebo gut microbiota using topic model-based cluster abundances, with groups defined according to treatment arm. B, Same analysis as in A, but with groups defined according to subsequent development of grade II–IV aGVHD or not. C, Comparison between early post-FMT versus early post-placebo samples in topic model-based cluster abundances. D, Same analysis as in C, but with groups defined based on the occurrence of subsequent grade II–IV aGVHD. Samples are early post-FMT/placebo. E, Principal coordinates analysis of pre-FMT/placebo gut microbiota using topic model-based cluster abundances, with groups defined according to GVHD prophylaxis. P values in A, B, and E are from an adonis test with 999 permutations, with percent variation explained by each axis is shown in parentheses. 95% ellipses are shown. P values in C are from a Wilcoxon test after Bonferroni correction. Comparisons in D were not statistically significant. In C and D, each box shows the median (horizontal middle line) and interquartile range. Whisker lines indicate nonoutlier maximum and minimum values. A small jitter is included for better visualization. aGVHD: acute graft-versus-host disease; FMT: fecal microbiota transplantation; PC: principal coordinate; PTCy: posttransplantation cyclophosphamide.